1-(2-tert-butoxycarbonyl-pentyl)cyclopentanecarboxylic acid | 337962-91-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(2-tert-butoxycarbonyl-pentyl)cyclopentanecarboxylic acid
• 英文别名: 1-[2-[(2-Methylpropan-2-yl)oxycarbonyl]pentyl]cyclopentane-1-carboxylic acid
• CAS: 337962-91-1
• 化学式: C₁₆H₂₈O₄
• 分子量: 284.396
• InChiKey: OTMYJDCCQQZEOM-UHFFFAOYSA-N

物化性质

• 沸点：
  380.7±15.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-tert-butoxycarbonyl-pentyl)cyclopentanecarboxylic acid 在 1-羟基苯并三唑 、 N,N'-羰基二咪唑 作用下， 反应 1.0h， 以100%的产率得到2-(1-Hydrazinocarbonyl-cyclopentylmethyl)-pentanoic acid tert-butyl ester
  参考文献：
  名称：

  Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides

  摘要：

  Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)

  DOI：

  10.1021/jm060133g
• 作为产物：
  描述：

  3-溴丙酸叔丁酯 在 palladium on activated charcoal 氢气 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， -78.0~20.0 ℃ 、103.42 kPa 条件下， 反应 6.25h， 生成 1-(2-tert-butoxycarbonyl-pentyl)cyclopentanecarboxylic acid
  参考文献：
  名称：

  Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder

  摘要：

  A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P'(1) and P'(2) regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.002

文献信息

• Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder
  作者：David C. Pryde、Andrew S. Cook、Denise J. Burring、Lyn H. Jones、Stephanie Foll、Michelle Y. Platts、Vivienne Sanderson、Martin Corless、Alan Stobie、Donald S. Middleton

  DOI：10.1016/j.bmc.2006.10.002

  日期：2007.1.1

  A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P'(1) and P'(2) regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study. (c) 2006 Elsevier Ltd. All rights reserved.
• Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides
  作者：David C. Pryde、Graham N. Maw、Simon Planken、Michelle Y. Platts、Vivienne Sanderson、Martin Corless、Alan Stobie、Christopher G. Barber、Rachel Russell、Laura Foster、Laura Barker、Christopher Wayman、Piet Van Der Graaf、Peter Stacey、Debbie Morren、Christopher Kohl、Kevin Beaumont、Sara Coggon、Michael Tute

  DOI：10.1021/jm060133g

  日期：2006.7.1

  Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)